Pharm/Biotech
Resources

Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

Pharm Stocks

FDA Links

FDA Warning Letters

FDA Doc/cGMP

Pharm/Biotech Events

Consultants

Advertiser Info

Newsletter Subscription

Web Links

Suggestions

Site Map
 

 

 

 

Title:  Method for the treatment of symptoms related to normal hormonal variations in women

United States Patent:  6,569,471

Issued:  May 27, 2003

Inventors:  Winther; Kaj (Copenhagen, DK); Hedman; Christer (Molnlycke, SE); Karnerud; Lars (Tenhult, SE)

Assignee:  Natumin Pharma AB (Huskvarna, SE)

Appl. No.:  942967

Filed:  August 31, 2001

Abstract

A method for the treatment of symptoms related to normal hormonal variations in women during fertile, peri- and post-menopausal age, by the administering of a composition comprising, as active ingredients, a water and/or fat-soluble cytosolic extract of pollen, optionally combined with Royal Jelly and Vitamin E.

DETAILED DESCRIPTION OF THE INVENTION

The active composition in the invention is a new remedy with the aim to be beneficial for the treatment of symptoms related to variations in the normal sex hormone pattern, such as the above mentioned. It is a combination of natural health products and comprises

a cytosolic pollen-pistil extract (PI 82),

a cytosolic pollen grain extract (GC FEM), and optionally

Royal Jelly, a substance produced by worker honey bees,

Vitamin E

Further, common drug processing compounds may be included such as diluents, glidants, lubricants, disintegrants, flavoring and coloring agents well known to the man skilled in the art of pharmaceutical sciences. The active ingredients can be included in formulations of any form, such as tablets, powders, granules, and tinctures or included in foodstuff of different origin, e.g. as functional food.

PI 82 is a cytosolic pollen-pistil extract rich in superoxide dismutase (SOD) mimics. The source of PI 82 is freshly harvested pollen grains and pistils. The pollen and pistils are allowed to react under very specific conditions. Substances obtained in this reaction are SOD mimics, flavanoids, tannins and polyphenols. In vitro studies have shown that the extract has high superoxide dismutase activity and prevents the formation of free radicals Experiences from double blind patient investigation show that PI 82 protects the body from free radicals and their negative influence on the body. Furthermore PI 82 improves the red cell function, thus improving oxygen perfusion to different tissues.

GC FEM is another water-soluble cytosolic extract from pollen. The cytoplasm content of the pollen contains in addition to the above-mentioned substances high amount of carbohydrates and protein. Amongst the proteins carotenoids and flavanoids are found. It also contains traces of estrogen substances.

The PI82 and GC FEM extracts are selected and harvested primarily from Poaceae. The extracts are treated to achieve germinal openings of the pollen as well as to minimize risk for allergic pollen reactions.

Royal Jelly is produced by the salivary glands of the worker honeybees from various plant materials. It contains a rich source of e.g. pantothenic acid, which has been called an anti-stress vitamin. It is preferably included in the composition in lyophilized form.

Test of the Effects on Symptoms Relating to Normal Variations of the Sex Hormone Pattern of Women of Fertile Age

A double-blind study was performed to investigate the efficacy and tolerability of the active composition in comparison to placebo in outpatients suffering from symptoms relating to normal variations in the sex hormone pattern of women. Patients with depression and anxiety were excluded.

The trial was performed on 29 women aged 27 to 54 years (mean 39.4 years), with regular menstrual cycles of 24 to 34 days. Criteria for admission were women aged 20 to 54 years with regular menses complaining of symptoms related to variations in the normal sex hormone pattern.

After a pre-study screening, half of the patients (Group A) took 2 placebo tablets twice daily, starting on the first day after menstruation and continued this treatment for two menstrual cycles, i.e. treatment period 1. The other half (Group 13) followed the same regimen, but they were administered 2 tablets twice daily each tablet comprising 120 mg PI 82, 36 mg GC FEM, 6 mg Royal Jelly and 10 mg Vitamin B. Thereafter, and without any "wash-out" period, each group crossed over to the other medication for another two menstrual cycles, i.e. treatment period 2. Both groups started their medication periods at the same time. No formal rules for withdrawal, other that the patient's own wish to withdraw, were considered necessary. No dropouts due to protocol deviations were recorded.

Statistical Analysis

A non-parametric method (Wilcoxon signed-rank, matched pair analysis) was used for analysis of differences between treatment scores, on an intention to treat basis. A p-value of 0.05 or less was adopted as the acceptable significance level. All numerical values have been reduced to 3 significant figures. With 29 patients available for evaluation, a day-to-day variation of 12%, a Type I error risk of 5%, and a Type II error risk of 10%, it would be possible to detect a score difference of 16%. To detect a possible "carry-over" effect it was decided that a separate statistical analysis of Group A and B should also be performed (cf. Table 13 and 14). An independent institution outside the clinic performed the statistical analysis.

Drug Formulations, Randomization and Blinding

The active composition and placebo tablets were formulated and packed to be indistiguishable for patients as well as for doctor and nurse. Treatments were allotted at random by computer generation for clusters of four individuals. The code list was generated and kept outside the clinic until the study had been completed. Drug formulations were packed and labeled for one month's treatment, and with a code number identifying the patient.

Results

Effects were analyzed as differences in scores for placebo and treatment with the disclosed composition, respectively.

Of the symptoms from the first test protocol, evaluated with VAS (visual analog scale) by patients, the product significantly reduced four as compared to placebo, viz. irritability (p<0.05), dysphoria (p<0.02), feeling of being bloated (p<0.05), and edema (p<0.02). The reduction in scores amounted to 39%, 36%, 41%, and 53% respectively. The reduced awareness of edema agrees well with the 57% reduction in gain in body weight. Tendencies of effects are also shown for mastalgia and headache. The letters "ns" below means "not significant". A spillover effect might be obtained from the treatment with the active compound to the placebo test. According to later follow-up tests, reported in Table 13 and 14, remarkably good effects were obtained.

The scope of the invention is as defied in the appended claims.

Irritability Score

During the first cycle the irritability score (visual analogue scales 1-10) was 4.2 during placebo treatment as compared to 3.1 during treatment with the active composition. The corresponding figures for the second cycle was 4.4 for placebo and 2.8 for the active composition. The difference between placebo and the active composition was statistically significant between the two treatments during the second cycle, while there was a tendency of improvement during the first. The score was statistically significant lower during the second the active composition period compared to the first (p<0.05), and a carry-over effect was observed.
 

                             TABLE 1
    Irritability score (VAS 0-10) during treatment with Placebo and the active
          composition (n = 29) at each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean         4.2         3.1         4.4         2.8
        Range       0-9.4       0-9.5       0-9.3       0-9.5
        S.D.         3.3         3.0         3.4         3.1
        p-value      ns                        p < 0.05

Dysphoria Score

During the first cycle the dysphoria score (visual analogue scales 1-10) was 3.1 during placebo treatment as compared to 2.6 during the active composition treatment. The corresponding figures for the second cycle was 3.9 for placebo and 2.3 for the active composition. The difference between placebo and the active composition was statistically significant between the two treatments dung the second cycle, while there was a tendency of improvement during the first.

 

                             TABLE 2
    Dysphoria score (VAS 0-10) during treatment with Placebo and the active
          composition (n = 29) at each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean         3.1         2.6         3.9         2.3
        Range       0-7.8       0-9.5       0-9.2       0-9.5
        S.D.         2.7         3.1         3.1         2.9
        p-value      ns                        p < 0.02

Bloating Score

During the first cycle the bloating score (visual analogue scales 1-10) was 3.9 during placebo treatment as compared to 2.4 during the active composition treatment. The corresponding figures for the second cycle was 3.7 for placebo and 2.2 for the active composition. The difference between placebo and the active composition was statistically significant between the two treatments for the first cycle and on the borderline on the second cycle (0.054). There was a significant carry-over effect.

 

                             TABLE 3
    Bloating score (VAS 0-10) during treatment with Placebo and the active
          composition (n = 29) at each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean         3.9         2.4         3.7         2.2
        Range       0-9.5       0-9.5       0-9.5       0-9.5
        S.D.         3.0         2.9         3.6         2.9
        p-value   p < 0.05               p = 0.054

Edema Score

During the first cycle the edema score (visual analogue scales 1-10) was 3.3 during placebo treatment as compared to 2.2 during the active composition treatment. The corresponding figures for the second cycle was 3.2 for placebo and 1.7 for the active composition. The difference between placebo and the active composition was statistically significant between the two treatments during the second cycle. A significant carry-over effect was found.

 

                             TABLE 4
    Edema score (VAS 0-10) during treatment with Placebo and the active
          composition (n = 29) at each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean         3.3         2.2         3.2         1.7
        Range       0-10        0-9.5       0-10        0-9.5
        S.D.         3.4         3.1         3.6         2.7
        p-value      ns                        p < 0.02


Mastalgia Score

During the first cycle the mastalgia score (visual analogue scales 1-10) was 3.3 during placebo treatment as compared to 2.9 during treatment with the active composition. The corresponding figures for the second cycle was 3.5 for placebo and 2.5 for the active composition. The differences between placebo and the active composition were not statistically significant between the two treatments.

 

                             TABLE 5
    Mastalgia score (VAS 0-10) during treatment with Placebo and the active
          composition (n = 29) at each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean         3.3         2.9         3.5         2.5
        Range       0-10        0-10        0-10        0-8.3
        S.D.         3.4         3.2         3.8         2.9
        p-value      ns                      ns

Weight Increase

During the first cycle the patients weight increase was 1.2 kg during placebo treatment as compared to 1.0 during treatment with the active compound. The corresponding figures for the second cycle was 1.4 for placebo and 0.6 for the active compound. The difference between placebo and the active compound was statistically significant between the two treatments during the second cycle. It was a statistically significant difference between the first the active compound period and the second. A significant carry-over effect was found.

 

                             TABLE 6
    Weight (kg) increase in connection with PMTS during treatment with
    Placebo and the active compound (n = 29) at each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean         1.2         1.0         1.4         0.6
        Range       0-5.5        0-3         0-5         0-3
        S.D.         1.3         1.0         1.3         0.8
        p-value      ns                        p < 0.01

Tension Score

During the first cycle the tension score (visual analogue scales 1-10) was 3.4 during placebo treatment as compared to 2.6 during treatment with the active compound. The corresponding figures for the second cycle was 3.7 for placebo and 2.5 for the active compound. The difference between placebo and the active compound was not statistically significant between the two treatments during any of the cycles, even if it was a strong tendency of improvement during the second (p=0.060). There was a statistically significant carry-over effect between the periods.

 

                             TABLE 7
    Tension score (VAS 0-10) during treatment with Placebo and the active
            compound (n = 29) at each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean         3.4         2.6         3.7         2.5
        Range       0-8.2       0-9.5       0-9.2       0-9.5
        S.D.         2.7         3.2         3.0         3.0
        p-value      ns                      ns

Headache Score

During the first cycle the headache score (visual analogue scales 1-10) was 3.7 during placebo treatment as compared to 2.1 during treatment with the active composition. The corresponding figures for the second cycle was 3.0 for placebo and 2.4 for the active composition. The differences between placebo and the active composition were not statistically significant between the two treatments.

 

                             TABLE 8
    Headache score (VAS 0-10) during treatment with Placebo and the active
          composition (n = 29) at each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean         3.7         2.1         3.0         2.4
        Range       0-10        0-8.9       0-9.5       0-9.5
        S.D.         3.3         2.8         3.4         3.1
        p-value      ns                      ns

Sleep Disturbances Score

During the first cycle the sleep disturbances score (visual analogue scales 1-10) was 2.8 during placebo treatment as compared to 2.0 during treatment with the active composition. The corresponding figures for the second cycle was 3.1 for placebo and 2.5 for the active composition. The differences between placebo and the active composition were not statistically significant between the two treatments.

 

                             TABLE 9
    Sleep disturbances score (VAS 0-10) during treatment with Placebo and
     the active composition (n = 29) at each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean         2.8         2.0         3.1         2.5
        Range       0-10        0-8.7       0-10        0-9.3
        S.D.         3.3         3.1         3.6         3.3
        p-value      ns                      ns

Safety, Heart Rate

No statistically significant differences between placebo and the active composition were found between the two treatments.

 

                             TABLE 10
    Heart rate after treatment with Placebo and the active composition
               (n = 29) after each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean        74.2        76.3        75.4        77.6
        Range       64-90       64-94       56-88       68-92
        S.D.         6.7         8.5         8.1         6.5
        p-value      ns                      ns

Systolic Blood Pressure

No statistically significant differences between placebo and the active composition were found between the two treatments.

 

                             TABLE 11
    Systolic blood pressure after treatment with Placebo and the active
         composition (n = 29) after each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean        114.5       114.8       112.1       113.5
        Range      90-135      90-150      95-125      90-130
        S.D.         12.0        13.9        8.5         10.4
        p-value      ns                      ns

Diastolic Blood Pressure

No statistically significant differences between placebo and the active composition were found between the two treatments.

 

                             TABLE 12
    Diastolic blood pressure after treatment with Placebo and the active
         composition (n = 29) after each menstrual cycle.
                   Placebo     Active      Placebo     Active
                  1st Cycle 1st Cycle 2nd Cycle 2nd Cycle
        Mean        77.4        77.1        78.1        79.4
        Range       60-90       60-85       70-90       70-90
        S.D.         6.4         7.0         5.3         5.9
        p-value      ns                      ns

A further statistical analyze is given in Table 13. The analyze was performed in line with the test of Wilcoxon test performed above. However, the participants obtained placebo during the first two treatment periods and the active composition during the two second treatment periods. The treatment with the active composition shows an unexpected and remarkably better effect as compared to the placebo treatment.

 

                                                      TABLE 13
                                                       Group A
                                   Mentrual cycle number
                           1         2           3             4
                                         Treatment
                        Placebo   Placebo  Active Femal  Active Femal
                                           Code
         P value matrix
                          AP1       AP2         AF1           AF2      AP1 vs
     AP2  AP2 vs AF1  AF1 vs AF2  AP2 vs AF2
    Tension            4.1+/-2.9 4.2+/-3.3   1.7+/-2.8     1.2+/-2.4       ns
             0.0134      0.0117      0.0012
    Irritability       4.9+/-3.5 4.7+/-3.8   2.1+/-2.5     1.4+/-2.5       ns
             0.0261      0.0020      0.0081
    Dysphoria          3.2+/-2.4 4.7+/-3.1   1.6+/-2.7     1.4+/-2.3       ns
             0.0107     (0.0907)      0.0024
    Weight change (kg) 1.5+/-1.6 1.6+/-1.6   0.6+/-0.9     0.4+/-0.5       ns
             0.0239     ns           0.0039
    Edema              4.3+/-3.7 4.2+/-3.8   0.5+/-0.8     0.5+/-0.8       ns
             0.0039     ns           0.0010
    Swelling (bloating) 4.7+/-2.3 4.4+/-3.6   1.2+/-1.2     0.9+/-1.6       ns
              0.0245     ns           0.0107
    Breast tension     4.1+/-3.4 3.8+/-3.8   2.5+/-3.0     1.4+/-2.6       ns
            ns           0.0195      0.0105
    Headache           4.0+/-3.6 3.5+/-3.7   0.9+/-1.2     1.6+/-3.0       ns
             0.0137     ns           0.0371
    Sleep disturbance  4.5+/-3.6 5.0+/-3.9   2.2+/-3.1     2.6+/-3.6       ns
             0.0266     ns           0.0081
    Overall wellbeing  3.2+/-1.3 3.4+/-1.5   1.5+/-1.2     1.5+/-1.1       ns
             0.0048     ns           0.0012
    Interf. social/prof. life 3.7+/-2.7 3.7+/-3.3   1.2+/-1.6     0.8+/-1.8
       ns           0.0093     (0.0781)      0.0034


TABLE 14 Group B Mentrual cycle number 1 2 3 4 Treatment Active Active comp. comp. Placebo Placebo Code P value matrix BF1 BF2 BP1 BP2 BF1 vs BF2 BF2 vs BP1 BP1 vs BP2 BF2 vs BF2 Tension 3.6+/-3.3 3.9+/-3.2 2.6+/-2.4 3.1+/-2.5 ns ns ns ns Irritability 4.3+/-3.1 4.3+/-3.2 3.5+/-2.9 4.1+/-2.9 ns ns ns ns Dysphoria 3.5+/-3.6 3.2+/-3.4 2.9+/-3.0 3.0+/-2.9 ns ns ns ns Weight change (kg) 1.4+/-1.0 0.8+/-1.0 0.8+/-0.8 1.1+/-0,9 0.0239 ns ns ns Edema 4.1+/-3.7 2.9+/-3.4 2.4+/-2.9 2.1+/-3.0 0.0176 ns ns ns Swelling (bloating) 3.7+/-3.4 3.6+/-3.6 3.1+/-3.1 3.1+/-3.6 ns ns ns ns Breast tension 3.4+/-3.4 3.6+/-3.1 2.5+/-3.3 3.3+/-4.1 ns ns ns ns Headache 3.4+/-3.5 3.2+/-3.1 3.4+/-3.0 2.5+/-3.2 na ns ns ns Sleep disturbances 1.8+/-3.5 2.4+/-3.2 1.0+/-1.7 1.0+/-1.5 ns ns ns 0.0371 Overall wellbeing 2.8+/-1.4 2.8+/-1.4 2.6+/-1.4 2.6+/-1.4 ns ns ns ns Interf. social/prof. life 2.2+/-2.2 2.6+/-3.2 1.6+/-2.4 1.7+/-2.5 ns ns ns ns

During placebo no adverse events were reported. During the first cycle of the active composition treatment three patients noted a shortened menstrual cycle and one patient reported dizziness. During the second cycle with the active composition 5 patients reported a shorter menstrual cycle than normal. Apart from these events the patients tolerated the active composition very well. The lack of severe adverse events is also obvious from Tables 10-12 above.

The results from these studies show that the active composition had a strong effect on tension, irritability, dysphoria, weight gain, edema, bloating, mastalgia, headache, sleep disturbances, overall wellbeing and interference in the social and professional life. The active composition was well tolerated by the patients.

It is interesting to note that the effect of the active composition was more pronounced during the second menstrual cycle compared to the first cycle of active treatment. This indicates that the treatment should be continued for at least two cycles before it should be evaluated whether the product works for the individual patient. For one of the ingredients included in the active composition--PI 82--a similar observation has been made regarding the effect on See radical formation. The onset of effect is seen first after a month treatment. Another reason for this may be that the effect of the active composition continues after having been withdrawn. The observed carry-over effect may indicate his. This effect may be one of the reasons why the efficacy of the active composition is not optimal during the first cycle, i.e. it may be that the onset of efficacy for the product is faster than the present data indicate. This is supported by the data from an open pilot study were the effects were as good during the first menstrual cycle as during the second.

The mode of action is with present scientific knowledge not known. As the product contains three different natural constituents, each with a theoretically contributing effect, the combination of these may be a reason for the observed effect. The constituents PI 82 and GC FEM contain SOD mimics such as flavanoids, tannin polyphenols and carotenoids. These SOD mimics have an effect on free radical formation, which may be a factor involved in redistribution of fluids, including edema, seen under stress situation. An improved oxygen perfusion may also be a contributing effect.

Vitamin E is added to the composition as an active ingredient or as an antioxidant and stabilizer for the tablet formulation.

Test of the Effects on Symptoms Relating to Normal Variations of the Sex Hormone Pattern of Women in the Peri- and Post-Menopause

Menopause, which is caused by a lowering of the production of FEMale sex hormones at the age around 50, can to many women generates unwanted symptoms such as hot flushes, attacks of sweating, muscle and possibly joint pain, sleep disturbances, dysphoria, nervousness, mood swings, headache, palpitations (enhanced frequency of heart rate), dry mucous membranes and pain during intercourse, urinary disturbances such as stress incontinent, frequent passing water and pain/irritability of the bladder and urethra during the process of passing water etc.

All these symptoms reflect age related changes which hitherto only have been alleviated effectively by the administration of FEMale sex hormones like estrogen and the like. By the administration of the present active composition, previously known only as a remedy to alleviate symptoms related to Pre-Menstrual Syndromes in common, surprisingly and unexpected a new remedy is obtained, which can relieve and cure the symptoms obstructing the normal life of women in the peri- and post-menopause without negative adverse effects.

The menopause starts around the age of 48-55 years. Four out of 5 women have disturbing menopause symptoms for at least one year and 25% of women have menopause symptoms fore more than 5 years. Three out of four women suffer from hot flushes and many women suffer from dysphoria, mood swings, decreased libido etc. Half of all women have severe symptoms and in a population of 5 million inhabitants, 200,000 women will constantly be in the period of life where menopause trouble is disrupting their life.

Test Mode

Ten women with an average age of 50.8 (range from 46 to 55) years were tested for the trial. All of them had been diagnosed to suffer from climacteric disorders. The menstruation had ceased for 5 women while being irregular for 5. None of the women obtained contemporaneous hormone therapy.

Each of the women obtained one tablet comprising the active ingredients in an amount of 120.0 mg PI 82, 36.0 mg GC FEM and 6.0 mg Royal Jelly, twice daily, morning and evening. The treatment did not affect pulse, or systolic or diastolic blood pressure.

All trials related to VAS (visual analogous scales) on symptoms relating to variations in the normal sex hormone pattern of women in the peri- and post-menopause. The women obtained an interrogation formulae and were requested to estate the symptoms disclosed in the formula according to a scale from 1 to 4, wherein a higher value implies a better result. The results of he tests are compiled in the enclosed Table 14. Low values express favorable results. All statistical calculations are Wilcoxon test for matched pairs, if not otherwise stated, VAS scales were performed on menopausal hot flashes, tendencies of sweating, palpitations, sleep disorders, vertigo, muscle pains, headache, difficulties in passing water (pollakuria), stress incontinence, dysphoria, dry-vaginal and mucous membranes, arthralgia, water retention (edema), irritability, and variations in mood.

The impact of active composition on different menopausal symptoms is shown in Table 15. The participating women evaluated their conditions as regards the symptoms disclosed in Table 15.

 

                             TABLE 15
    The impact of active composition on different menopausal symptoms.
                 Mean value (standard deviation).
                                     Treatment of  Treatment of
                                     active        active
                         Without     composition   composition
    Menopausal symptoms  treatment   1 month       2 months
    Hot flushes          3.08 (2.27) 2.81 (2.03)   1.33 (2.00)**
    Sweating tendencies  3.94 (2.29) 2.75 (2.37)   1.73 (2.54)
    Palpitations         2.66 (2.74) 1.88 (1.37)   1.31 (1.66)#
    Muscle pain          3.40 (3.19) 2.19 (1.42)   2.08 (2.40)**
    Headache             3.77 (2.84) 2.38 (2.20)*** 2.53 (1.98)***
    Stress incontinence or 1.73 (2.34) 1.15 (1.44)   0.72 (0.85)#
    frequent passing water
    (pollakiuria)
    Dysphoria            3.41 (2.05) 2.16 (1.27)*  1.60 (1.22)**
    Dry vaginal and mucous 3.02 (2.88) 1.36 (1.31)*** 1.52 (2.32)***
    membranes an/or pain
    during intercourse
    Joint pain           3.94 (2.82) 1.91 (1.03)   1.48 (1.30)**
    Mood                 3.05 (2.26) 2.72 (1.90)   1.73 (1.15)
    Edema                6.04 (2.53) 4.48 (1.93)*  3.28 (1.59)**
    Energy loss          4.99 (2.15) 3.82 (1.60)*  2.72 (2.21)***
    Irritability         3.18 (2.55) 2.20 (1.78)*** 1.61 (1.24)*
    Sleep disturbances   4.28 (3.89) 3.00 (3.07)   2.87 (3.09)
    Mood swings          3.33 (2.16) 2.31 (1.07)   1.81 (1.63)#
    Oversensitivity      4.03 (2.06) 2.70 (2.07)*  2.01 (1.79)**
    # = border line significance
    * = p < 0.05
    ** = p < 0.02
    *** = p < 0.01

Hot flushes: significant (p<0.02) after two months.

Sweating tendencies: significant (p<0.05) after two months

Palpitations: more than 50% reduction (borderline significant).

Muscle pans: significant (p<0.02) after one month and borderline after two months.

Headache: highly significant (p<0.01) after one and two months.

Stress incontinence and/or pollakuria: reduction of about 60%, borderline significant.

Dysphoria: significant after one and two months (p<0.05 and p<0.02).

Dry vaginal or mucous membranes and/or pain during intercourse: significant after one and two months (p<0.01 and p<0.01)>50% reduction.

Joint pain: significant after two months (p<0.02)

Mood: not significant, however a favorable change of about 40% is obvious.

Edema/water retention: reduction of more than 50%, significant after one and two months (p<0.05 and p<0.02).

Energy loss: marked enhancement, significant after one and two months (p<0.05 and p<0.01).

Irritability: reduced by 50% (p<0.01 and p<0.05).

Sleep disturbances show a tendency of effect but is not significant.

Mood swings: borderline significant after two months.

Oversensitivity: significant better after one and two months (p<0.05 and p<0.02).

If all 19 VAS scores were added to a common "over all well being score" a clearly positive effect is shown for 8 of 10 participants, only two were unchanged. Thus, the improvement is significant (p<0.02).

At a direct inquiry of all ten participants whether they have had any advantages or use of the treatment, 6 of them clearly said, "yes" while four answered "don't know" (p<0.05, Chi square).

Below is given an Example of a tablet used according to the invention.

            Active ingredients:
            PI 82 (pollen pistil extract)        120.0 mg
            GC FEM (pollen extract)              36.0 mg
            Secondary ingredients:
            ROYAL JELLY (freeze dried)            6.0 mg
            VITAMIN E 50%                        20.0 mg
            Other ingredients:
            Mikrocrystallin cellulose            87.0 mg
            Dicalciumphosphate                   87.0 mg
            Magnesium stearate                    4.0 mg
            Uncoated tablet weight              360.0 mg
            Coating:
            Shellac                      approx. 2.64 mg
            Talc                         approx. 0.36 mg
            Total weight                 approx. 363.0 mg

Claim 1 of 16 Claims

What is claimed is:

1. A method for the treatment of symptoms related to normal hormonal variations in women during fertile, peri- and post-menopausal age, by the administration of a composition comprising, as active ingredients, a water and/or fat-soluble cytosolic extract of pollen alone (GC FEM), an extract of pollen and pistils (PI 82), or a combination of said extracts, optionally combined with Royal Jelly and Vitamin E.
 


____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.

 

 

[ Outsourcing Guide ] [ Cont. Education ] [ Software/Reports ] [ Training Courses ]
[ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ]

[ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ]
[ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ]
[ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ]
[ Site Map ]